NASDAQ:LPTX - Leap Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.30
  • Forecasted Upside: 233.33 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$1.59
▲ +0.09 (6.00%)
1 month | 3 months | 12 months
Get New Leap Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LPTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LPTX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$5.30
▲ +233.33% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Leap Therapeutics in the last 3 months. The average price target is $5.30, with a high forecast of $8.00 and a low forecast of $2.50. The average price target represents a 233.33% upside from the last price of $1.59.
Buy
The current consensus among 5 polled investment analysts is to buy stock in Leap Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/8/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/6/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/5/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/4/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/2/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/31/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/30/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/29/2020

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/16/2020Raymond JamesSet Price TargetOutperform$2.50Low
i
11/10/2020Raymond JamesSet Price TargetOutperform$2.50Low
i
9/22/2020Raymond JamesSet Price TargetOutperform$2.50Low
i
8/17/2020Raymond JamesSet Price TargetOutperform$2.50Medium
i
8/17/2020HC WainwrightLower Price TargetBuy$5.00 ➝ $4.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
7/19/2020LADENBURG THALM/SH SHReiterated RatingMarket Perform ➝ Buy$8.00High
i
6/29/2020Piper SandlerInitiated CoverageOverweight$6.00High
i
6/12/2020Raymond JamesSet Price TargetOutperform$2.50High
i
5/19/2020HC WainwrightReiterated RatingBuy$2.50 ➝ $5.00Medium
i
5/17/2020Raymond JamesSet Price TargetOutperform$2.50Medium
i
4/24/2020Raymond JamesSet Price TargetOutperform$2.50Low
i
Rating by David Novak at Raymond James
3/17/2020Raymond JamesSet Price TargetOutperform$2.50Low
i
Rating by David Novak at Raymond James
3/17/2020HC WainwrightLower Price TargetBuy$3.25 ➝ $2.50High
i
Rating by Swayampakula Ramakanth at HC Wainwright
2/10/2020Robert W. BairdInitiated CoverageOutperform$6.00High
i
1/8/2020Raymond JamesUpgradeMarket Perform ➝ Outperform$2.50Low
i
Rating by David Novak at Raymond James
11/15/2019HC WainwrightReiterated RatingBuy$3.25High
i
Rating by Swayampakula Ramakanth at HC Wainwright
11/15/2019Raymond JamesDowngradeOutperform ➝ Market PerformHigh
i
Rating by David Novak at Raymond James
9/19/2019Raymond JamesSet Price TargetOutperform$5.00Low
i
Rating by David Novak at Raymond James
9/13/2019Raymond JamesInitiated CoverageOutperform$5.00Medium
i
12/19/2018Raymond JamesLower Price TargetOutperform ➝ Outperform$13.00 ➝ $8.00Medium
i
11/13/2018HC WainwrightSet Price TargetBuy$13.00Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
10/23/2018HC WainwrightSet Price TargetBuy$13.00Medium
i
Rating by Swayampakula Ramakanth at HC Wainwright
4/12/2018HC WainwrightInitiated CoverageBuy$12.50Low
i
Rating by S. Ramakanth at HC Wainwright
3/7/2017LADENBURG THALM/SH SHInitiated CoverageBuy ➝ Buy$18.00N/A
i
3/1/2017CitigroupInitiated CoverageMarket PerformN/A
i
2/28/2017Raymond JamesInitiated CoverageOutperform ➝ Outperform$13.00N/A
i
(Data available from 11/29/2015 forward)
Leap Therapeutics logo
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. The company's clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 that is in multiple clinical trials for treating esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, and prostate cancer. Its clinical stage programs also include TRX518, a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor in patients with solid tumors. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.
Read More

Today's Range

Now: $1.59
$1.50
$1.62

50 Day Range

MA: $1.88
$1.49
$2.31

52 Week Range

Now: $1.59
$0.69
$3.18

Volume

791,378 shs

Average Volume

704,799 shs

Market Capitalization

$94.86 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.58